Treace to Present at the Sidoti Small Cap Conference
Rhea-AI Summary
Treace (Nasdaq: TMCI) will present at the Sidoti Small Cap Conference on Thursday, June 18, 2026, starting around 1:45 pm ET.
A live webcast and replay will be available on Treace’s investor relations website, where the company also posts information that may be important to investors.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TMCI
On the day this news was published, TMCI gained 3.84%, reflecting a moderate positive market reaction. Argus tracked a peak move of +11.6% during that session. Argus tracked a trough of -4.0% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $289.66M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
TMCI gained 13.4% while key peers were mostly down: KIDS -0.49%, BVS -1.42%, CBLL -0.65%, CTKB -2.3%, with only SRDX slightly up 0.26%, pointing to a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 08 | Q1 2026 earnings | Negative | +4.7% | Reported revenue decline and net loss but reaffirmed 2026 guidance. |
| Apr 24 | Earnings call date | Neutral | +8.8% | Announced date and access details for Q1 2026 results call. |
| Apr 07 | Product launch news | Positive | -6.9% | Announced first surgical cases with new SuperBite screw system, expanding market. |
| Feb 27 | FY 2025 earnings | Neutral | -11.4% | Reported modest revenue growth with improved adjusted EBITDA but ongoing losses. |
| Feb 24 | Clinical data update | Positive | -2.0% | Presented favorable ALIGN3D recurrence and union data plus new device previews. |
Recent news often saw price moves that did not track the apparent tone: positive product or clinical updates and mixed earnings data have been followed by both rallies and sell-offs, with several notable downside reactions.
Over the last few months, Treace reported Q4 2025 revenue of $62.5M and full-year 2025 revenue of $212.7M, with adjusted EBITDA loss improving to $3.9M. Subsequent Q1 2026 revenue was $47.2M, down 10% year-over-year, and net loss was $18.0M. Alongside these results, Treace announced new products such as the SuperBite™ Compression Screw System and highlighted positive clinical data including an 8.4% 48‑month recurrence rate in ALIGN3D, showing ongoing product and clinical development.
Market Pulse Summary
This announcement highlights Treace’s upcoming presentation at the Sidoti Small Cap Conference on June 18, 2026 at 1:45 pm ET, signaling continued engagement with investors. In the months leading up to this, the company reported Q1 2026 revenue of $47.2M with a net loss of $18.0M and introduced new products and positive clinical data. Investors may watch future earnings, commercialization milestones, and additional clinical updates for further clarity on execution.
Key Terms
midfoot deformities medical
nasdaqgs financial
AI-generated analysis. Not financial advice.
PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET.
A live webcast and replay of the presentation will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide® patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
